de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: ...

Key Takeaways. Draft guidance targets reduction/elimination of nonhuman primate testing for monoclonal antibodies, signaling higher regulatory receptivity to alternative nonclinic ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

Add Yahoo as a preferred source to see more of our stories on Google. The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a ...

Balasegaram is executive director of the Global Antibiotic Research & Development Partnership. No matter how carefully we use the antibiotics we have, drug resistant infections will continue to gain ...

A newly discovered mechanism renders antibiotic-resistant bacteria vulnerable by disabling both their individual resistance ...

Although the past decade has been marked by lack of innovation in the field of antibiotics development, that trend is changing, according to data from Reportlinker. According to the data, 109 ...

Antibiotic resistance genes (ARGs)—segments of DNA that help bacteria survive the effects of antibiotics—can be present in ...

DENVER The last time a new tuberculosis drug was developed, Richard Nixon was in the White House. That drug, Rifampin, "was the biggest thing to hit TB in 30 years," said Dr. Michael Iseman, a ...

As the world grapples with the daunting challenge of antibiotic-resistant superbugs, a ray of hope emerges from the scientific community. Recent strides in medical research have led to the development ...